Navidea biopharmaceuticals inc. announces preclinical therapeutic research collaboration with imv inc. to explore the potential combinatory effect with their platform-based immunotherapies

Navidea biopharmaceuticals, inc. and imv inc. have entered a preclinical research collaboration to explore the potential combinatory effect of their platform-based immunotherapies. the purpose of this collaboration is to conduct preclinical studies to evaluate the combinatory effect of navidea’s proprietary activated macrophage targeting therapeutics along with imv’s dpx-based immunotherapies. navidea and imv will jointly conduct the research throughout the duration of the study.
NAVB Ratings Summary
NAVB Quant Ranking